Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk

Breast

Volumn 20, Issue 1, 2011, Pages 66-70

  Ashok, Varun ^a   Dash, Chiranjeev ^a   Rohan, Thomas E ^b   Sprafka, J Michael ^c   Terry, Paul D ^a,d  

^a EMORY UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Kendle International Inc   (United States)

^d UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Disease risk; Epidemiology; Selective cyclooxygenase 2 inhibitors

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; VALDECOXIB;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79451475199     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.07.004     Document Type: Article

References (38)

1. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62(3):625-631.
2. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60(5):1306-1311.
3. Diaz-Cruz E.S., Shapiro C.L., Brueggemeier R.W. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005, 90(5):2563-2570.
4. Hla T., Bishop-Bailey D., Liu C.H., Schaefers H.J., Trifan O.C. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 1999, 31(5):551-557.
5. Ristimaki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62(3):632-635.
6. Ouellet M., Riendeau D., Percival M.D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A 2001, 98(25):14583-14588.
7. Rich S.A. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345(23):1709.
8. Baron J.A., Greenberg E.R. Could aspirin really prevent colon cancer?. N Engl J Med 1991, 325(23):1644-1646.
9. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355(9):873-884.
10. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355(9):885-895.
11. Sharpe C.R., Collet J.P., McNutt M., Belzile E., Boivin J.F., Hanley J.A. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000, 83(1):112-120.
12. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5(2):138-146.
13. Harris R.E., Kasbari S., Farrar W.B. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999, 6(1):71-73.
14. Harris R.E., Chlebowski R.T., Jackson R.D., Frid D.J., Ascenseo J.L., Anderson G., et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003, 63(18):6096-6101.
15. Cotterchio M., Kreiger N., Sloan M., Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10(11):1213-1217.
16. Johnson T.W., Anderson K.E., Lazovich D., Folsom A.R. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002, 11(12):1586-1591.
17. Moorman P.G., Grubber J.M., Millikan R.C., Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003, 14(10):915-922.
18. Bosetti C., Gallus S., La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 2006, 17:871-888.
19. Coogan P.F., Rao S.R., Rosenberg L., Palmer J.R., Strom B.L., Zauber A.G., et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999, 29(2):72-76.
20. Harris R.E., Namboodiri K., Stellman S.D., Wynder E.L. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 1995, 24(2):119-120.
21. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res 1993, 53(6):1322-1327.
22. Paganini-Hill A., Chao A., Ross R.K., Henderson B.E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989, 299(6710):1247-1250.
23. Egan K.M., Stampfer M.J., Giovannucci E., Rosner B.A., Colditz G.A. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996, 88(14):988-993.
24. Neugut A.I., Rosenberg D.J., Ahsan H., Jacobson J.S., Wahid N., Hagan M., et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998, 7(10):869-873.
25. Langman M.J., Cheng K.K., Gilman E.A., Lancashire R.J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320(7250):1642-1646.
26. Meier C.R., Schmitz S., Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002, 22(3):303-309.
27. Khuder S.A., Mutgi A.B. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001, 84(9):1188-1192.
28. Arpino G., Laucirica R., Elledge R.M. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005, 143(6):446-457.
29. Lanza-Jacoby S., Miller S., Flynn J., Gallatig K., Daskalakis C., Masferrer J.L., et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003, 12(12):1486-1491.
30. Howe L.R., Subbaramaiah K., Patel J., Masferrer J.L., Deora A., Hudis C., et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002, 62(19):5405-5407.
31. Rozic J.G., Chakraborty C., Lala P.K. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001, 93(4):497-506.
32. Grosch S., Maier T.J., Schiffmann S., Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98(11):736-747.
33. Bak A.W., McKnight W., Li P., Del Soldato P., Calignano A., Cirino G., et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998, 62(23):367-373.
34. Thompson H.J., Briggs S., Paranka N.S., Piazza G.A., Brendel K., Gross P.H., et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 1995, 87(16):1259-1260.
35. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002, 94(8):585-591.
36. Schonthal A.H. Induction of apoptosis by celecoxib in cell culture: an uncertain role for cyclooxygenase-2. Cancer Res 2007, 67(11):5575-5576. author reply 5576.
37. Harris R.E., Beebe-Donk J., Alshafie G.A. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006, 6:27. PHST-2006/01/30 [ahead of print].
38. Terry M.B., Gammon M.D., Zhang F.F., Tawfik H., Teitelbaum S.L., Britton J.A., et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004, 291(20):2433-2440.